May 16, 2016
ICGCmed launched this April (see story on ICGCmed’s launch). We spoke to Dr. Peter Lichter, Head of the Division of Molecular Genetics at the German Cancer Research Center (DKFZ) about why ICGCmed is needed and what the next steps are to ensure the consortium can meet its ambitious goals.
Why is ICGCmed necessary, and why now?
Researchers worldwide are currently exploring how to bring more precision oncology to the clinic. The goal is to develop a new approach to how we treat cancer patients that is more specific to their individual type of cancer. Currently, at many places clinical studies are being launched addressing similar questions. An international network of such studies would not only harmonize these initiatives and develop common standards, it would also greatly accelerate the process of validating the concept and provide guidelines to physicians who are not yet familiar with this approach.
April 17, 2016
International Cancer Genome Consortium for Medicine (ICGCmed) launches today, will link genomics to clinical information and health
New Orleans – (April 17, 2016) The International Cancer Genome Consortium (ICGC) today announced plans to launch the International Cancer Genome Consortium for Medicine (ICGCmed), a new phase in the Consortium’s evolution that will link genomics to clinical information and health.
The collaborative project will build upon the vast database of genomic discoveries of the ICGC, which, since its launch in 2007, has been mapping 25,000 different cancer genomes in 50 different tumour types and making this data freely available to qualified researchers around the world.